• Obesity was defined by the presence of a diagnosis code containing obesity or obese BMI designation ≥30 kg/m2
  • Risks of stroke/SE and major bleeding were evaluated using Cox proportional hazard models with robust sandwich estimates among the matched cohorts
  • Two subgroup analyses evaluated risks of stroke/SE and major bleeding for:

(A) Patients prescribed standard-dose NOACs (apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg), and

(B) Morbidly obese patients (defined using diagnosis codes indicating morbid obesity or BMI ≥40 kg/m2)

1|2